5AM Ventures
Venture capital · Menlo Park, California, United States
Portfolio collected from the firm’s website, last checked Jul 26, 2026.Raises and exits come from each company’s own SEC and company records.
20Deep-tech portfolio16 active
4Portfolio exitsAcquired or listed
0Raises, 12 monthsLatest: Renasant Bio
25Co-investorsShare a portfolio company
Portfolio · 20 companies
| Company | Sector | Status | Latest raise | Raised |
|---|---|---|---|---|
| Renasant Bio | Biotech | Active | Jul 14, 2025 | $55.5M |
| Deverra Therapeutics | Biotech | Active | Sep 18, 2023 | $2.5M |
| Radionetics Oncology | Biotech | Active | Aug 15, 2023 | $54.2M |
| Ensoma | Biotech | Active | May 23, 2023 | $119.6M |
| Expansion Therapeutics | Biotech | Active | Oct 12, 2021 | $73.6M |
| ARTBIO | Biotech | Active | — | — |
| Faraday Biosciences | Biotech | Active | — | — |
| GlycoEra | Biotech | Active | — | — |
| Igenica | Biotech | Active | — | — |
| Inipharm | Biotech | Active | — | — |
| Karius | Medtech | Active | — | — |
| Mendra | Biotech | Active | — | — |
| NodThera | Biotech | Active | — | — |
| Nouscom | Biotech | Active | — | — |
| Precede Biosciences | Medtech | Active | — | — |
| Reprotech | Medtech | Active | — | — |
| Skye Bioscience | Biotech | Public | Mar 27, 2024 | $166.7M |
| Entrada Therapeutics | Biotech | Public | Apr 13, 2021 | $150.9M |
| Surrozen | Biotech | Public | Jun 23, 2020 | $50.0M |
| Ginkgo Bioworks | Biotech | Public | Sep 2, 2015 | $50.0M |
Peer ranks
Portfolio size#16
Portfolio exits#49
Raises, 12 months#88
Co-investors#79
Co-investors
- Atlas VentureVenture capital2 shared
- Third Rock VenturesVenture capital2 shared
- Alexandria Venture InvestmentsVenture capital1 shared
- Bioeconomy CapitalVenture capital1 shared
- BioMADEVenture capital1 shared
- Biospring PartnersVenture capital1 shared
- Cormorant Asset ManagementVenture capital1 shared
- DCVC BioVenture capital1 shared
- Foresite CapitalVenture capital1 shared
- F-Prime CapitalVenture capital1 shared
Sectors
- Biotech17
- Medtech3
Portfolios are collected from investors’ own websites and matched to tracked deep-tech companies by name; duplicate listings of the same firm are merged. Exits and raises come from each company’s own record: Form D through the latest filing.